OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in cari...
We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.
--------
10:52
The Accelerated Approval Pathway
Weighing the Pros & Cons of the accelerated approval pathway as it relates to oncology. An updated draft guidance document from FDA regarding this pathway and some compelling data regarding the public's perceived value of newly approved drugs for cancer.
Article: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Forest R, et al. Lancet Oncology 2024. Link: https://doi.org/10.1016/S1470-2045(24)00596-5
--------
13:14
2024 New Drug Review
Looking back at new approvals from 2024 - what to keep, re-gift, or return?
And yes, as soon as this was recorded 2 new drugs were approved.
--------
18:03
A Feast Of Updates
Lots of recent clinical trial updates to discuss:
AQUILA: Daratumumab for high-risk smoldering multiple myeloma
Checkmate 8HW: Nivo/Ipi for MSI-high/MMRd metastatic colorectal cancer
DESTINY-Breast06: T-DXd in HER2-low MBC after hormonal treatment, but without previous chemo for MBC
ARMANI: Switch maintenance ramucirumab-paclitaxel in metastatic gastric/GEJ cancer
HELEN-006: Neoadjuvant nab-paclitaxel/trastuzumab/pertuzumab vs. TCHP in breast cancer
SONIA: finally published!
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Ireland